EUVIMEDObjevte EUVIMED
Systematische ÜbersichtMetaanalyseVergleichsstudieÜbersichtsarbeitOpen access · CC BY 4.0

Efficacy of SGLT2 Inhibitors With or Without Metformin Compared With Metformin Alone in Women With Polyendocrine Metabolic Ovarian Syndrome: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Ahmed Adel Mohamed iD, Moaz Feteih iD, Mostafa Elsayed Ahmed, Mark Makar Kadies iD, Ahmed Elsayed Elsayed Ibrahim iD, Menna Ibrahim, Yaser M Abusalem, Osama M Aldeeb iD, Abdelrahman M Aldeeb iD, Mohammad Shekho, Mohammed Dibas iD

Endocrinology, Diabetes & Metabolism · 2026-11 · 9 (6)

DOI: 10.1002/edm2.70397 ↗

At a glance

Systematische Übersicht in Endocrinology, Diabetes & Metabolism, published online on 2026-11-15. Written by Ahmed Adel Mohamed and 10 co-authors. Institution: Faculty of Medicine, Zagazig University, Zagazig, Egypt. Major MEDLINE topics: Metformin, Sodium-Glucose Transporter 2 Inhibitors, Polycystic Ovary Syndrome, Hypoglycemic Agents. 34 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Polycystic ovary syndrome (PCOS), recently redefined as polyendocrine metabolic ovarian syndrome (PMOS), is a common endocrine disorder of reproductive‐age women. Metformin remains first‐line therapy, whereas sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have emerged for their cardiometabolic effects. This study compared SGLT2 inhibitors, alone or with metformin, versus metformin alone in PMOS.

Methods

We performed a PRISMA‐guided systematic review and meta‐analysis of randomized controlled trials from PubMed, Scopus, Web of Science, Cochrane CENTRAL and Embase. Two reviewers independently screened, extracted data, assessed risk of bias (Cochrane RoB 2) and rated certainty using GRADE. Continuous outcomes were pooled as mean differences (MD) with 95% confidence intervals (CI) under a random‐effects model; heterogeneity was assessed with I 2 .

Results

Five trials (292 women) were included. SGLT2 inhibitors did not differ significantly from metformin in body weight (MD = −2.06 kg; 95% CI −5.79 to 1.68) or BMI (MD = −0.34 kg/m 2 ; 95% CI −0.78 to 0.10), or most hormonal, glycemic and anthropometric outcomes. However, they significantly reduced triglycerides (MD = −0.21 mmol/L; 95% CI −0.38 to −0.05) and diastolic blood pressure (MD = −1.79 mmHg; 95% CI −2.57 to −1.01), with a small increase in systolic blood pressure (MD = 0.97 mmHg; 95% CI 0.11–1.83). Certainty of evidence ranged from low to high.

Conclusion

SGLT2 inhibitors, alone or with metformin, did not differ significantly from metformin across most metabolic and endocrine outcomes, with modest benefits on triglycerides and diastolic blood pressure. Metformin remains first‐line therapy; SGLT2 inhibitors may be considered in selected patients pending larger trials.

Subjects

MeSH terms (MEDLINE)

MetforminSodium-Glucose Transporter 2 InhibitorsPolycystic Ovary SyndromeHypoglycemic AgentsMetabolic SyndromeHumansFemaleRandomized Controlled Trials as TopicDrug Therapy, CombinationTreatment Outcome

Author keywords

SGLT2 inhibitorsinsulin resistancemeta‐analysismetforminpolycystic ovary syndromepolyendocrine metabolic ovarian syndrome

Substances

MetforminSodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Authors and institutions

  • Faculty of Medicine, Zagazig University, Zagazig, Egypt.
  • Faculty of Medicine, Galala University, Suez, Egypt.
  • Faculty of Medicine, Minia University, Minia, Egypt.
  • Faculty of Medicine, Alexandria University, Alexandria, Egypt.
  • Faculty of Medicine, The University of Jordan, Amman, Jordan.
  • Faculty of Medicine, Cairo University, Cairo, Egypt.

ORCID profiles: Ahmed Adel Mohamed, Moaz Feteih, Mark Makar Kadies, Ahmed Elsayed Elsayed Ibrahim, Osama M Aldeeb, Abdelrahman M Aldeeb, Mohammed Dibas

Cite

APA

Mohamed, A. A., Feteih, M., Ahmed, M. E., Kadies, M. M., Ibrahim, A. E. E., Ibrahim, M., Abusalem, Y. M., Aldeeb, O. M., Aldeeb, A. M., Shekho, M., & Dibas, M. (2026). Efficacy of SGLT2 Inhibitors With or Without Metformin Compared With Metformin Alone in Women With Polyendocrine Metabolic Ovarian Syndrome: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism, 9(6). https://doi.org/10.1002/edm2.70397

Vancouver

Mohamed AA, Feteih M, Ahmed ME, Kadies MM, Ibrahim AEE, Ibrahim M, et al. Efficacy of SGLT2 Inhibitors With or Without Metformin Compared With Metformin Alone in Women With Polyendocrine Metabolic Ovarian Syndrome: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism. 2026;9(6). doi:10.1002/edm2.70397

BibTeX
@article{Mohamed2026,
  author = {Mohamed, Ahmed Adel and Feteih, Moaz and Ahmed, Mostafa Elsayed and Kadies, Mark Makar and Ibrahim, Ahmed Elsayed Elsayed and Ibrahim, Menna and Abusalem, Yaser M and Aldeeb, Osama M and Aldeeb, Abdelrahman M and Shekho, Mohammad and Dibas, Mohammed},
  title = {Efficacy of SGLT2 Inhibitors With or Without Metformin Compared With Metformin Alone in Women With Polyendocrine Metabolic Ovarian Syndrome: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2026},
  volume = {9},
  number = {6},
  doi = {10.1002/edm2.70397}
}
Start for free →